GlassScriptPhysician profile
Petrit Ndrio
NPI 1861432635
$16,191.20
in general payments reported to CMS, 2019-2025
40 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $2,107 · 2021: $2,689 · 2022: $2,687 · 2023: $2,549 · 2024: $3,073 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,585 · Education: $89.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,585.38 |
| Education | $89.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,732.97 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,490.97 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,169.14 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,097.48 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,072.97 | 2019-2025 | Rexulti |
| Corium, LLC | $986.06 | 2021-2025 | Azstarys |
| Tris Pharma INC | $942.18 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Alkermes, INC. | $823.59 | 2019-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $734.26 | 2021-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $670.94 | 2020-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $594.02 | 2019-2024 | Jornay Pm |
| Almatica Pharma LLC | $580.03 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Neurocrine Biosciences, INC. | $556.91 | 2019-2025 | Ingrezza |
| Allergan, INC. | $455.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $385.17 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $362.29 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $321.32 | 2019-2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $317.24 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $287.05 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $279.04 | 2021-2025 | Trintellix |
| Adlon Therapeutics L.P. | $264.18 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $142.68 | 2019-2021 | |
| Indivior INC. | $137.61 | 2024-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $115.87 | 2022-2023 | Quviviq |
| Eisai INC. | $92.21 | 2020-2022 | |
| Owp Pharmaceuticals, INC. | $78.29 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $77.30 | 2025 | Jornay Pm |
| Neuronetics, INC. | $58.88 | 2020-2022 | |
| Noven Therapeutics, LLC | $55.71 | 2024 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $55.14 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.28 | 2024 | |
| Alfasigma USA, INC. | $36.18 | 2022 | |
| Vertical Pharmaceuticals, LLC | $34.79 | 2020-2024 | Relexxii |
| Harmony Biosciences LLC | $30.50 | 2021 | |
| Orexo US, INC. | $20.66 | 2025 | Zubsolv |
| Biogen, INC. | $20.09 | 2024 | |
| Avanir Pharmaceuticals, INC. | $19.96 | 2022 | |
| Brainsway USA INC | $18.04 | 2024 | Brainsway Deep Tms System |
| Novo Nordisk INC | $17.90 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $17.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petrit Ndrio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.